PharmAsia News Notable Notes: China’s Outsourcing Costs Vs. Growth Potential
This article was originally published in PharmAsia News
Executive Summary
Analysts' views on the costs associated with outsourcing research to China remains mixed, but concerns regarding fluctuations in costs are minimized by opportunity for growth in China, according to Baird analyst Eric Coldwell